Twist Bioscience (TWST) and Centogene (CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases announced the launch of three next-generation sequencing NGS target enrichment panels to support rare disease and hereditary cancer research and support diagnostics. "There are over 7,000 rare diseases impacting over 350 million patients, many of whom are not diagnosed until the late stages of the disease. Our mission is to provide data-driven, life-changing answers as early as possible to ultimately accelerate the development of treatments," said Kim Stratton, Chief Executive Officer at CENTOGENE. "By partnering with Twist to develop these custom panels, we are enabling access to diagnostics and generating novel insights for the medical community, fueled by multidimensional data from the CENTOGENE Biodatabank." All three new Alliance Panels are highly curated using the CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. Identified sequences are then synthesized by Twist as biotinylated capture probes which are compatible with Twist’s library preparation solution and target enrichment workflows. The panels offered through Twist will include:
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TWST:
- Twist in research pact with with Astellas, eligible for milestone payments
- Twist Bioscience initiated with Outperform, $33 target at Scotiabank
- Twist Bioscience initiated with an Outperform at Scotiabank
- Azenta downgraded to In Line at Evercore ISI on share loss
- Twist Bioscience upgraded at Evercore ISI with accounting fears eased